- Home
- LDTC vs FBRX Comparison
LDTC vs FBRX Comparison
Compare LDTC & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDTC
- FBRX
- Stock Information
- Founded
- LDTC 2007
- FBRX N/A
- Country
- LDTC Canada
- FBRX United States
- Employees
- LDTC N/A
- FBRX N/A
- Industry
- LDTC Blank Checks
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- LDTC Finance
- FBRX Health Care
- Exchange
- LDTC Nasdaq
- FBRX Nasdaq
- Market Cap
- LDTC 7.9M
- FBRX 8.3M
- IPO Year
- LDTC N/A
- FBRX N/A
- Fundamental
- Price
- LDTC $0.32
- FBRX $5.55
- Analyst Decision
- LDTC Buy
- FBRX Strong Buy
- Analyst Count
- LDTC 3
- FBRX 3
- Target Price
- LDTC $1.00
- FBRX $81.25
- AVG Volume (30 Days)
- LDTC 157.6K
- FBRX 13.6K
- Earning Date
- LDTC 08-14-2024
- FBRX 11-14-2024
- Dividend Yield
- LDTC N/A
- FBRX N/A
- EPS Growth
- LDTC N/A
- FBRX N/A
- EPS
- LDTC N/A
- FBRX N/A
- Revenue
- LDTC $6,052,694.00
- FBRX N/A
- Revenue This Year
- LDTC N/A
- FBRX N/A
- Revenue Next Year
- LDTC $2.28
- FBRX N/A
- P/E Ratio
- LDTC N/A
- FBRX N/A
- Revenue Growth
- LDTC 2.76
- FBRX N/A
- 52 Week Low
- LDTC $0.22
- FBRX $4.11
- 52 Week High
- LDTC $11.20
- FBRX $21.25
- Technical
- Relative Strength Index (RSI)
- LDTC 59.16
- FBRX 58.76
- Support Level
- LDTC $0.28
- FBRX $4.44
- Resistance Level
- LDTC $0.35
- FBRX $5.90
- Average True Range (ATR)
- LDTC 0.04
- FBRX 0.37
- MACD
- LDTC 0.01
- FBRX 0.20
- Stochastic Oscillator
- LDTC 75.97
- FBRX 80.45
About LDTC LeddarTech Holdings Inc.
LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).